Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Inclusion criteria: * Patients with haematological or lymphoid malignancies with allogenic transplantation indication: * High risk follicular NHL, mantle HHC and other low grade NHC (e.g lymphoplasmacytic, extranodal or from marginal zone). 1. Disease that does not obtain a CR with Fludarabine or antiCD-20 including chemotherapy. 2. Relapse after autologous transplant. 3. Non candidates to autologous transplant in 2nd CR (e.g. mobilization failure, or persistent marrow infiltrate). * Poor prognosis chronic lymphoblastic leukaemia (CLL): Del 11q, Del 17p, complex cariotype; B symptoms, progressive low cell count by marrow infiltration, lymphocytosis or enlarged lymph nodes, or progressive spleen growth. * High grade lymphoma transformed from a low grade non Hodgkin's lymphoma or from a chronic lymphocitic leukaemia * High risk T peripheral lymphoma, with IPI \> or = 2, non susceptible of autologous transplant, or relapsed after autologous transplant * Primarily refractory high risk Hodgkin's disease, relapse in patients not susceptible of autologous transplant or relapse after autologous transplant. * High risk acute mieloblastic leukaemia (AML) in 1st CR, or AMC \> or = 2 CR, including AML after MDS and secondary AML. * High risk acute lymphoblastic leukaemia (ALL) because of poor response to induction chemotherapy (\>10% blasts day +14 or no RC day +28-35), or by cytogenetic criteria: Ph+ or 11q23. * High risk myelodisplastic syndromes (SMD) type RAEB-1 or AREB-2 with IPSS \>Int-1. * For the inclusion in transplant patients with ALL or AML must be in CR, patients with MDS must have \<10% blasts en la BM, and patients with lymphoid malignancies must show previous chemosensitivity, with PR or CR. * Patients 40 to 65 years old. Patients outside this age range could be included according to participating centres criteria. * Patients in the study population lacking a compatible related donor, and with a possible compatible unrelated donor (\>=9/10 by 10 alleles high resolution typing: HLA-A, B, C, DRB1, DQB1) to assign the patients to a risk in subgroup. * Signed informed consent. * Not fulfilling any of the following exclusion criteria. Exclusion Criteria: * Liver (≥ x3 UNL), kidney (GF \<40ml/min), cardiac (LVEF \<40%) or respiratory (DLCO \& FVC \<40% of expected) function tests impairment. * HIV injection. * Absence of signed informed consent. * Progressive disease previous to transplant or not fulfilling the above mentioned response criteria. * Other co-morbidities that contraindicate CT. * Pregnant and/or breast-feeding women or with pregnancy risk by inadequate contraception. * Life expectancy \<6 months. * Mental or psychiatric deficiency impeding adequate understanding and consent to therapy * Hypersensitivity as shown by anaphylactic reaction to any of the DRUGS used in the trial. * Active infectious process.